Mahita LLC dba PushMyCart – FDA Warning Letter, Sep 30, 2025

On November 17, 2025, the U.S. Food and Drug Administration (FDA) issued a Warning Letter to Mahita LLC, operating as PushMyCart. The letter follows an FDA review of the company"s website (pushmycart.com) in September 2025, which revealed the sale of several unapproved drug products. The primary violation involves PushMyCart offering products such as "Morbillinum 10M CH," "Cornus Circinata 12 CH," and "REPL Dr. Advice No.45 Glaucoma Drop," among others. These products are marketed with claims to treat, cure, or prevent serious conditions like measles, hepatitis, cancer, diabetes, and Parkinson"s. The FDA classifies these as unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), and their introduction into interstate commerce violates sections 301(d) and 505(a). The agency highlighted that claims for serious illnesses, especially with ophthalmic products, pose significant public health risks, potentially leading consumers to delay or forgo effective medical treatments. Mahita LLC is required to cease the sale of these unapproved drugs and respond to the FDA, detailing the corrective actions taken to address these violations.